Hepatitis C: Diagnosis and Management
- PMID: 34913652
Hepatitis C: Diagnosis and Management
Abstract
Screening recommendations and treatment guidelines for hepatitis C virus (HCV) infection have been updated. People at the greatest risk of HCV infection are those between 18 and 39 years of age and those who use injection drugs. Universal screening with an anti-HCV antibody test with follow-up reflex HCV RNA polymerase chain reaction testing for positive results to confirm active disease is recommended at least once for all adults 18 years and older and during each pregnancy. Any person with ongoing risk factors should be screened periodically as long as the at-risk behavior persists. One-time screening is recommended for patients younger than 18 years with risk factors. For treatment-naive adults without cirrhosis or with compensated cirrhosis, a simplified treatment regimen consisting of eight weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvir results in greater than 95% cure rates. Undetectable HCV RNA 12 weeks after completing therapy is considered a virologic cure (i.e., sustained virologic response). A sustained virologic response is associated with lower all-cause mortality and improves hepatic and extrahepatic manifestations, cognitive function, physical health, work productivity, and quality of life. In patients with compensated cirrhosis, posttreatment surveillance for hepatocellular carcinoma and esophageal varices should include abdominal ultrasonography (with or without alpha fetoprotein) every six months and upper endoscopy every two to three years. In the absence of cirrhosis, no liver-related follow-up is recommended.
Similar articles
-
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16. Lancet Gastroenterol Hepatol. 2020. PMID: 32682494 Clinical Trial.
-
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.J Viral Hepat. 2020 Aug;27(8):762-769. doi: 10.1111/jvh.13317. Epub 2020 May 25. J Viral Hepat. 2020. PMID: 32386099 Review.
-
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27. Gastroenterology. 2018. PMID: 29958855 Clinical Trial.
-
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14. Lancet Infect Dis. 2017. PMID: 28818546 Clinical Trial.
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review.
Cited by
-
Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.Fundam Clin Pharmacol. 2023 Aug;37(4):726-738. doi: 10.1111/fcp.12889. Epub 2023 Mar 25. Fundam Clin Pharmacol. 2023. PMID: 36931725 Review.
-
Screening for co-infections in patients with substance use disorders and severe bacterial infections.Ther Adv Infect Dis. 2022 Oct 17;9:20499361221132132. doi: 10.1177/20499361221132132. eCollection 2022 Jan-Dec. Ther Adv Infect Dis. 2022. PMID: 36277297 Free PMC article.
-
Revolution in the diagnosis and management of hepatitis C virus infection in current era.World J Hepatol. 2022 Apr 27;14(4):647-669. doi: 10.4254/wjh.v14.i4.647. World J Hepatol. 2022. PMID: 35646260 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical